Journal of Vascular Surgery
Volume 44, Issue 5 , Pages 971-975 , November 2006

Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events

Presented as a poster at the Thirty-fourth Annual Symposium of the Society for Clinical Vascular Surgery, Las Vegas, Nev, March 8-11, 2006.

  • Louis L. Nguyen, MD, MBA, MPH

      Affiliations

    • Division of Vascular and Endovascular Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationReprint requests: Louis L. Nguyen, MD, MBA, MPH, Division of Vascular and Endovascular Surgery and the Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115
    • ,
  • Stuart R. Lipsitz, ScD

      Affiliations

    • Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Dennis F. Bandyk, MD

      Affiliations

    • Division of Vascular Surgery, University of South Florida, Tampa, Fla
    • ,
  • Alexander W. Clowes, MD

      Affiliations

    • Division of Vascular Surgery, University of Washington, Seattle, Wash
    • ,
  • Gregory L. Moneta, MD

      Affiliations

    • Division of Vascular Surgery, Oregon Health Sciences University, Portland, Ore
    • ,
  • Michael Belkin, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Michael S. Conte, MD

      Affiliations

    • Division of Vascular and Endovascular Surgery, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass
    • Center for Surgery & Public Health, Brigham & Women’s Hospital, Harvard Medical School, Boston, Mass

Received 3 April 2006 ,Accepted 19 July 2006.

References 

  1. Maini BS, Orr RK, O’Mara P, Hendershott T. Outcomes and resource utilization in a managed care setting for lower extremity vein bypass grafts. Am J Surg. 1996;172:113–116discussion 117
  2. Munoz E, Cohen J, Zelnick R, et al. Hospital costs by clinical parameters for peripheral vascular surgical DRGs. J Cardiovasc Surg (Torino). 1989;30:58–63
  3. Hobart DC, Nicholas GG, Reed JF, Nastasee SA. Carotid endarterectomy outcomes research: reduced resource utilization using a clinical protocol. Cardiovasc Surg. 2000;8:446–451
  4. Arora P, Kausz AT, Obrador GT, et al. Hospital utilization among chronic dialysis patients. J Am Soc Nephrol. 2000;11:740–746
  5. Van Acker K, Oleen-Burkey M, De Decker L, et al. Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. Diabetes Res Clin Pract. 2000;50:87–95
  6. Huber TS, Seeger JM. Dartmouth Atlas of Vascular Health Care review: impact of hospital volume, surgeon volume, and training on outcome. J Vasc Surg. 2001;34:751–756
  7. Conte MS, Lorenz TJ, Bandyk DF, et al. Design and rationale of the PREVENT III clinical trial: edifoligide for the prevention of infrainguinal vein graft failure. Vasc Endovasc Surg. 2005;39:15–23
  8. Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005;42:456–464discussion 464-5
  9. Conte MS, Bandyk DF, Clowes AW, et al. Results of PREVENT III: a multi-center, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–751
  10. Landry GJ, Moneta GL, Taylor LM, et al. Comparison of procedural outcomes after lower extremity reversed vein grafting and secondary surgical revision. J Vasc Surg. 2003;38:22–28
  11. Antonello M, Frigatti P, Battocchio P, et al. Open repair versus endovascular treatment for asymptomatic popliteal artery aneurysm: results of a prospective randomized study. J Vasc Surg. 2005;42:185–193
  12. Kazmers A, Jacobs LA, Perkins AJ. Outcomes after lower-extremity reconstruction in DRGs 478 and 479. J Surg Res. 2000;88:18–22

 Competition of interest: Drs Bandyk, Clowes, Moneta, Belkin, and Conte have each served as a paid consultant to Corgentech, Inc. Dr Conte has served as a paid consultant to Bristol-Myers Squibb. Dr Moneta owns stock in Bristol-Myers that predated the PREVENT III trial.

PII: S0741-5214(06)01360-7

doi: 10.1016/j.jvs.2006.07.035

Journal of Vascular Surgery
Volume 44, Issue 5 , Pages 971-975 , November 2006

Article Tools

* Image Usage & Resolution